<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZAROXOLYN- metolazone tablet </strong><br>UNITHER Manufacturing LLC<br></p></div>
<h1>Zaroxolyn® Tablets<br>(metolazone tablets, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">Rx Only</p>
<p><span class="Bold"><span class="Underline">DO NOT INTERCHANGE:</span><br>DO NOT INTERCHANGE ZAROXOLYN TABLETS AND OTHER FORMULATIONS OF METOLAZONE THAT SHARE ITS SLOW AND INCOMPLETE BIOAVAILABILITY AND ARE <span class="Underline">NOT</span> THERAPEUTICALLY EQUIVALENT AT THE SAME DOSES TO MYKROX® TABLETS, A MORE RAPIDLY AVAILABLE AND COMPLETELY BIOAVAILABLE METOLAZONE PRODUCT.  FORMULATIONS BIOEQUIVALENT TO ZAROXOLYN AND FORMULATIONS BIOEQUIVALENT TO MYKROX SHOULD <span class="Underline">NOT</span> BE INTERCHANGED FOR ONE ANOTHER.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ZAROXOLYN Tablets (metolazone tablets, USP) for oral administration contain 2½ or 5 mg of metolazone, USP, a diuretic/saluretic/antihypertensive drug of the quinazoline class.</p>
<p>Metolazone has the molecular formula C<span class="Sub">16</span>H<span class="Sub">16</span>ClN<span class="Sub">3</span>S, the chemical name 7-chloro-1, 2, 3, 4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide, and a molecular weight of 365.83.  The structural formula is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=16026409-e821-4680-a114-24c1761d6690&amp;name=zaroxolyn-01.jpg"></p>
<p>Metolazone is only sparingly soluble in water, but more soluble in plasma, blood, alkali, and organic solvents.</p>
<p>Inactive Ingredients:  Magnesium stearate, microcrystalline cellulose and dye:  2½ mg-D&amp;C Red No. 33; 5 mg-FD&amp;C Blue No. 2.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">ZAROXOLYN (metolazone) is a quinazoline diuretic, with properties generally similar to the thiazide diuretics.  The actions of ZAROXOLYN result from interference with the renal tubular mechanism of electrolyte reabsorption.  ZAROXOLYN acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule.  Sodium and chloride ions are excreted in approximately equivalent amounts.  The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion.  ZAROXOLYN does not inhibit carbonic anhydrase.  A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration.  This action has been demonstrated in animals by micropuncture studies.</p>
<p>When ZAROXOLYN Tablets are given, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and saluresis usually begin within one hour and may persist for 24 hours or more.  For most patients, the duration of effect can be varied by adjusting the daily dose.  High doses may prolong the effect.  A single daily dose is recommended.  When a desired therapeutic effect has been obtained, it may be possible to reduce dosage to a lower maintenance level.</p>
<p>The diuretic potency of ZAROXOLYN at maximum therapeutic dosage is approximately equal to thiazide diuretics.  However, unlike thiazides, ZAROXOLYN may produce <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in patients with glomerular filtration rates below 20 mL/min.</p>
<p>ZAROXOLYN and furosemide administered concurrently have produced marked <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in some patients where <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> was refractory to treatment with maximum recommended doses of these or other diuretics administered alone.  The mechanism of this interaction is unknown (see <a href="#Warnings">WARNINGS</a> and <a href="#Interactions">PRECAUTIONS, Drug Interactions</a>).</p>
<p>Maximum blood levels of metolazone are found approximately eight hours after dosing.  A small fraction of metolazone is metabolized.  Most of the drug is excreted in the unconverted form in the urine.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ZAROXOLYN is indicated for the treatment of salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span> including:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> accompanying <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>;</li>
<li><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> accompanying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal diseases</span>, including the <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> and states of diminished renal function.</li>
</ul>
<p>ZAROXOLYN is also indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, alone or in combination with other antihypertensive drugs of a different class.  MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  A dose titration is necessary if MYKROX Tablets are to be substituted for ZAROXOLYN in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  See package circular for MYKROX Tablets (UCB).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Usage In Pregnancy</h2>
<p class="First">The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard.  Diuretics do not prevent development of <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span>, and there is no evidence that they are useful in the treatment of developed toxemia.</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy.  ZAROXOLYN is indicated in pregnancy when <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> is due to pathologic causes, just as it is in the absence of pregnancy (see <a href="#Precautions">PRECAUTIONS</a>).  <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span> in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary.  There is <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, including <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, in the majority of pregnant women.  If this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> produces <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, increased recumbency will often provide relief.  In rare instances, this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may cause extreme <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> which is not relieved by rest.  In these cases, a short course of diuretics may be appropriate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Contra"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>, <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> or <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">precoma</span>, known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metolazone.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Rapid Onset <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> And/Or <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></h2>
<p class="First">Rarely, the rapid onset of severe <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and/or <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> has been reported following initial doses of thiazide and non-thiazide diuretics.  When symptoms consistent with severe <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> appear rapidly, drug should be discontinued and supportive measures should be initiated immediately.  Parenteral electrolytes may be required. Appropriateness of therapy with this class of drugs should be carefully reevaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may occur with consequent <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>.  Serum potassium should be determined at regular and appropriate intervals, and dose reduction, potassium supplementation or addition of a potassium-sparing diuretic instituted whenever indicated.  <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> is a particular hazard in patients who are digitalized or who have or have had a <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>; dangerous or fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may be precipitated.  <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> is dose related.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2>Concomitant Therapy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3.1"></a><p></p>
<h3>Lithium</h3>
<p class="First">In general, diuretics should not be given concomitantly with lithium because they reduce its renal clearance and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.  Read prescribing information for lithium preparations before use of such concomitant therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3.2"></a><p></p>
<h3>Furosemide</h3>
<p class="First">Unusually large or prolonged losses of fluids and electrolytes may result when ZAROXOLYN is administered concomitantly to patients receiving furosemide (see <a href="#Interactions">PRECAUTIONS, Drug Interactions</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2>Other Antihypertensive Drugs</h2>
<p class="First">When ZAROXOLYN is used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2>Cross-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></h2>
<p class="First">Cross-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> may occur when ZAROXOLYN is given to patients known to be allergic to sulfonamide-derived drugs, thiazides, or quinethazone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6"></a><p></p>
<h2>Sensitivity Reactions</h2>
<p class="First">Sensitivity reactions (e.g., <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>) may occur with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and may occur with the first dose of ZAROXOLYN.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold"><span class="Underline">DO NOT INTERCHANGE</span><br>DO NOT INTERCHANGE ZAROXOLYN TABLETS AND OTHER FORMULATIONS OF METOLAZONE THAT SHARE ITS SLOW AND INCOMPLETE BIOAVAILABILITY AND ARE <span class="Underline">NOT</span> THERAPEUTICALLY EQUIVALENT AT THE SAME DOSES TO MYKROX TABLETS, A MORE RAPIDLY AVAILABLE AND COMPLETELY BIOAVAILABLE METOLAZONE PRODUCT.  FORMULATIONS BIOEQUIVALENT TO ZAROXOLYN AND FORMULATIONS BIOEQUIVALENT TO MYKROX SHOULD <span class="Underline">NOT</span> BE INTERCHANGED FOR ONE ANOTHER.</span></p>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3>Fluid And Electrolytes</h3>
<p class="First">All patients receiving therapy with ZAROXOLYN Tablets should have serum electrolyte measurements done at appropriate intervals and be observed for clinical signs of fluid and/or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>: namely, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.  In patients with severe <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> accompanying <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, a low-salt syndrome may be produced, especially with hot weather and a low-salt diet.  Serum and urine electrolyte determinations are particularly important when the patient has protracted <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or is receiving parenteral fluids.  Warning signs of imbalance are: dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> may occur at any time during long term therapy and, on rare occasions, may be life threatening.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> is increased when larger doses are used, when <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> is rapid, when severe liver disease is present, when corticosteroids are given concomitantly, when oral intake is inadequate or when excess potassium is being lost extrarenally, such as with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Thiazide-like diuretics have been shown to increase the urinary excretion of magnesium; this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Glucose"></a><a name="section-7.1.2"></a><p></p>
<h3>Glucose Tolerance</h3>
<p class="First">Metolazone may raise blood glucose concentrations possibly causing <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></h3>
<p class="First">ZAROXOLYN regularly causes an increase in serum uric acid and can occasionally precipitate gouty attacks even in patients without a prior history of them.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">Azotemia</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">Azotemia</span>, presumably prerenal <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, may be precipitated during the administration of ZAROXOLYN.  If <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> worsen during treatment of patients with severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, ZAROXOLYN should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">Use caution when administering ZAROXOLYN Tablets to patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  As most of the drug is excreted by the renal route, accumulation may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> may occur; this may be potentiated by alcohol, barbiturates, narcotics, or concurrent therapy with other antihypertensive drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.7"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> may infrequently occur with metolazone, especially in patients taking high doses of vitamin D or with high bone turnover states, and may signify hidden <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>.  Metolazone should be discontinued before tests for parathyroid function are performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.8"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></h3>
<p class="First">Thiazide diuretics have exacerbated or activated <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> and this possibility should be considered with ZAROXOLYN Tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information For Patients</h2>
<p class="First">Patients should be informed of possible adverse effects, advised to take the medication as directed, and promptly report any possible adverse reactions to the treating physician.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Interactions"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<h3>Diuretics</h3>
<p class="First">Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes (see <a href="#Warnings">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<h3>Other Antihypertensives</h3>
<p class="First">When ZAROXOLYN Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.  Dosage adjustments of other antihypertensives may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.3"></a><p></p>
<h3>Alcohol, Barbiturates, And Narcotics</h3>
<p class="First">The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.4"></a><p></p>
<h3>Digitalis Glycosides</h3>
<p class="First">Diuretic-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> can increase the sensitivity of the myocardium to digitalis.  Serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> can result.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.5"></a><p></p>
<h3>Corticosteroids Or ACTH</h3>
<p class="First">May increase the risk of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and increase salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.6"></a><p></p>
<h3>Lithium</h3>
<p class="First">Serum lithium levels may increase (see <a href="#Warnings">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.7"></a><p></p>
<h3>Curariform Drugs</h3>
<p class="First">Diuretic-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) – the most serious effect would be <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which could proceed to <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>.  Accordingly, it may be advisable to discontinue ZAROXOLYN three days before elective surgery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.8"></a><p></p>
<h3>Salicylates And Other Non-Steroidal Anti-Inflammatory Drugs</h3>
<p class="First">May decrease the antihypertensive effects of ZAROXOLYN Tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.9"></a><p></p>
<h3>Sympathomimetics</h3>
<p class="First">Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.10"></a><p></p>
<h3>Insulin And Oral Antidiabetic Agents</h3>
<p class="First">See <a href="#Glucose">Glucose Tolerance under PRECAUTIONS, General</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.11"></a><p></p>
<h3>Methenamine</h3>
<p class="First">Efficacy may be decreased due to urinary alkalizing effect of metolazone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.12"></a><p></p>
<h3>Anticoagulants</h3>
<p class="First">Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; dosage adjustments may be necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">None reported.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment Of Fertility</h2>
<p class="First">Mice and rats administered metolazone 5 days/week for up to 18 and 24 months, respectively, at daily doses of 2, 10, and 50 mg/kg, exhibited no evidence of a tumorigenic effect of the drug.  The small number of animals examined histologically and poor survival in the mice limit the conclusions that can be reached from these studies.</p>
<p>Metolazone was not mutagenic <span class="Italics">in vitro</span> in the Ames Test using <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA-97, TA-98, TA-100, TA-102, and TA-1535.</p>
<p>Reproductive performance has been evaluated in mice and rats.  There is no evidence that metolazone possesses the potential for altering reproductive capacity in mice.  In a rat study, in which males were treated orally with metolazone at doses of 2, 10, and 50 mg/kg for 127 days prior to mating with untreated females, an increased number of resorption sites was observed in dams mated with males from the 50 mg/kg group.  In addition, the birth weight of offspring was decreased and the pregnancy rate was reduced in dams mated with males from the 10 and 50 mg/kg groups.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">Reproduction studies performed in mice, rabbits, and rats treated during the appropriate period of gestation at doses up to 50 mg/kg/day have revealed no evidence of harm to the fetus due to metolazone.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, ZAROXOLYN Tablets (metolazone tablets, USP) should be used during pregnancy only if clearly needed.  Metolazone crosses the placental barrier and appears in cord blood.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-7.6.2"></a><p></p>
<h3>Non-Teratogenic Effects</h3>
<p class="First">The use of ZAROXOLYN Tablets in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus.  These hazards include fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions which have occurred in the adult.  It is not known what effect the use of the drug during pregnancy has on the later growth, development, and functional maturation of the child.  No such effects have been reported with metolazone.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.7"></a><p></p>
<h2>Labor And Delivery</h2>
<p class="First">Based on clinical studies in which women received metolazone in late pregnancy until the time of delivery, there is no evidence that the drug has any adverse effects on the normal course of labor or delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Metolazone appears in breast milk.  Because of the potential for serious adverse reactions in nursing infants from metolazone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established in controlled clinical trials.  There is limited experience with the use of ZAROXOLYN in pediatric patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4283942" conceptname="Bronchopulmonary dysplasia of newborn">bronchopulmonary dysplasia</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> and <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>.  Doses used generally ranged from 0.05 to 0.1 mg/kg administered once daily and usually resulted in a 1 to 2.8 kg <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> and 150 to 300 cc increase in urine output.  Not all patients responded and some gained weight. Those patients who did respond did so in the first few days of treatment.  Prolonged use (beyond a few days) was generally associated with no further beneficial effect or a return to baseline status and is not recommended.</p>
<p>There is limited experience with the combination of ZAROXOLYN and furosemide in pediatric patients with furosemide-resistant <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.  Some benefited while others did not or had an exaggerated response with <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> requiring fluid replacement.  Severe <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> was reported and there was a tendency for <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> to persist for up to 24 hours after ZAROXOLYN was discontinued.  <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span> has been reported in 1 neonate.  Close clinical and laboratory monitoring of all children treated with diuretics is indicated.  See <a href="#Contra">CONTRAINDICATIONS</a>, <a href="#Warnings">WARNINGS</a>, <a href="#Precautions">PRECAUTIONS</a>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of ZAROXOLYN did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">ZAROXOLYN is usually well tolerated, and most reported adverse reactions have been mild and transient.  Many ZAROXOLYN related adverse reactions represent extensions of its expected pharmacologic activity and can be attributed to either its antihypertensive action or its renal/metabolic actions.  The following adverse reactions have been reported. Several are single or comparably rare occurrences.  Adverse reactions are listed in decreasing order of severity within body systems.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, excessive <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, hemoconcentration, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Central And Peripheral Nervous System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">psychotic depression</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> (sometimes resulting in <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Dermatologic/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span> (TEN), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> (<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4023572" conceptname="Abdominal bloating">abdominal bloating</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>Hematologic</h2>
<p class="First">Aplastic/<span class="product-label-link" type="condition" conceptid="4218974" conceptname="Hypoplastic anemia">hypoplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>Metabolic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, increase in serum urea nitrogen (BUN) or creatinine, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint pain</span>, acute gouty attacks, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> or spasm.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.8"></a><p></p>
<h2>Other</h2>
<p class="First">Transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p>In addition, adverse reactions reported with similar antihypertensive-diuretics, but which have not been reported to date for ZAROXOLYN include: bitter taste, <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> (including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>), and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.  These reactions should be considered as possible occurrences with clinical usage of ZAROXOLYN.</p>
<p>Whenever adverse reactions are moderate or severe, ZAROXOLYN dosage should be reduced or therapy withdrawn.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Intentional overdosage has been reported rarely with metolazone and similar diuretic drugs.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Signs And Symptoms</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, electrolyte abnormalities, hemoconcentration and hemodynamic changes due to plasma <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> may occur.  In some instances depressed respiration may be observed.  At high doses, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> of varying degree may progress to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> within a few hours.  The mechanism of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> with thiazide overdosage is unknown.  Also, <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">GI irritation</span> and hypermotility may occur.  Temporary elevation of BUN has been reported, especially in patients with impairment of renal function.  Serum electrolyte changes and cardiovascular and renal function should be closely monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">There is no specific antidote available but immediate evacuation of stomach contents is advised.  Dialysis is not likely to be effective.  Care should be taken when evacuating the gastric contents to prevent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, especially in the stuporous or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> patient.  Supportive measures should be initiated as required to maintain hydration, electrolyte balance, respiration, and cardiovascular and renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Effective dosage of ZAROXOLYN should be individualized according to indication and patient response.  A single daily dose is recommended.  Therapy with ZAROXOLYN should be titrated to gain an initial therapeutic response and to determine the minimal dose possible to maintain the desired therapeutic response.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Usual Single Daily Dosage Schedules</h2>
<p class="First">Suitable initial dosages will usually <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in the ranges given.</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>:<br>  ZAROXOLYN 5 to 20 mg once daily.</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>:<br>  ZAROXOLYN 5 to 20 mg once daily.</p>
<p>Mild to moderate <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span>:<br>  ZAROXOLYN 2½ to 5 mg once daily.</p>
<p>New patients – MYKROX Tablets (metolazone tablets, USP) (see MYKROX package circular).  If considered desirable to switch patients currently on ZAROXOLYN to MYKROX, the dose should be determined by titration starting at one tablet (1/2 mg) once daily and increasing to two tablets (1 mg) once daily if needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Treatment Of Edematous States</h2>
<p class="First">The time interval required for the initial dosage to produce an effect may vary.  <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Diuresis</span> and saluresis usually begin within one hour and persist for 24 hours or longer.  When a desired therapeutic effect has been obtained, it may be advisable to reduce the dose if possible.  The daily dose depends on the severity of the patient's condition, sodium intake, and responsiveness.  A decision to change the daily dose should be based on the results of thorough clinical and laboratory evaluations.  If antihypertensive drugs or diuretics are given concurrently with ZAROXOLYN, more careful dosage adjustment may be necessary.  For patients who tend to experience <span class="product-label-link" type="condition" conceptid="4206307" conceptname="Paroxysmal nocturnal dyspnea">paroxysmal nocturnal dyspnea</span>, it may be advisable to employ a larger dose to ensure prolongation of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and saluresis for a full 24-hour period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Treatment Of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">The time interval required for the initial dosage regimen to show effect may vary from three or four days to three to six weeks in the treatment of elevated blood pressure.  Doses should be adjusted at appropriate intervals to achieve maximum therapeutic effect.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ZAROXOLYN Tablets (metolazone tablets, USP) are shallow biconvex, round tablets, and are available in two strengths:</p>
<p>2½ mg, pink, debossed "ZAROXOLYN" on one side, and "2½ " on reverse side.<br>  NDC 53014-975-71 Bottle of 100's</p>
<p>5 mg, blue, debossed "ZAROXOLYN" on one side, and "5" on reverse side.<br>  NDC 53014-850-71 Bottle of 100's</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].</p>
<p>Protect from light.  Keep out of the reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">For Medical Information</span></p>
<p>Contact:  Medical Affairs Department<br>Phone:  (866) 822-0068<br>Fax:  (770) 970-8859</p>
<p>UCB, Inc.<br>Smyrna, GA 30080</p>
<p>ZAROXOLYN is a registered trademark of UCB Manufacturing, Inc.<br>© 2014, UCB, Inc., Smyrna, GA 30080<br>All rights reserved.</p>
<p>Rev. 01/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 53014-850-71</p>
<p><span class="Bold">Zaroxolyn</span><span class="Sup">®</span><span class="Bold"> Tablets<br>(metolazone tablets, USP)<br>5 mg</span></p>
<p>Rx Only<br><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">ucb</span></p>
<p>Manufactured for:<br><span class="Bold">UCB, Inc.</span> Smyrna, GA 30080<br>® UCB Manufacturing, Inc.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=16026409-e821-4680-a114-24c1761d6690&amp;name=zaroxolyn-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2½ mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 53014-975-71</p>
<p><span class="Bold">Zaroxolyn</span><span class="Sup">®</span><span class="Bold"> Tablets<br>(metolazone tablets, USP)<br>2½ mg</span></p>
<p>Rx Only<br><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">ucb</span></p>
<p>Manufactured for:<br><span class="Bold">UCB, Inc.</span> Smyrna, GA 30080<br>® UCB Manufacturing, Inc.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2½ mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=16026409-e821-4680-a114-24c1761d6690&amp;name=zaroxolyn-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZAROXOLYN 		
					</strong><br><span class="contentTableReg">metolazone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53014-850</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>metolazone</strong> (metolazone) </td>
<td class="formItem">metolazone</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ZAROXOLYN;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53014-850-71</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017386</td>
<td class="formItem">11/27/1973</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZAROXOLYN 		
					</strong><br><span class="contentTableReg">metolazone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53014-975</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>metolazone</strong> (metolazone) </td>
<td class="formItem">metolazone</td>
<td class="formItem">2.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C Red No. 33</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ZAROXOLYN;2;1;2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53014-975-71</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017386</td>
<td class="formItem">11/27/1973</td>
<td class="formItem">04/30/2015</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>UNITHER Manufacturing LLC
							(079176615)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5f3c3e1a-936b-4134-ab2f-045516f46af5</div>
<div>Set id: 16026409-e821-4680-a114-24c1761d6690</div>
<div>Version: 7</div>
<div>Effective Time: 20150506</div>
</div>
</div> <div class="DistributorName">UNITHER Manufacturing LLC</div></p>
</body></html>
